{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:16:07Z","timestamp":1792808167408,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,6]]},"DOI":"10.7759\/cureus.50085","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T07:29:56Z","timestamp":1701934196000},"source":"Crossref","is-referenced-by-count":6,"title":["Lobeglitazone and Its Therapeutic Benefits: A Review"],"prefix":"10.7759","author":[{"given":"Balamurugan","family":"M","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarumathy","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robinson","family":"R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0272","article-title":"Lobeglitazone: a novel thiazolidinedione for the management of type 2 diabetes mellitus","volume":"45","author":"Bae J","year":"2021","unstructured":"Bae J, Park T, Kim H, Lee M, Cha BS. Lobeglitazone: a novel thiazolidinedione for the management of type 2 diabetes mellitus. Diabetes Metab J. 2021, 45:326-36. 10.4093\/dmj.2020.0272","journal-title":"Diabetes Metab J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092843","article-title":"Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial","volume":"9","author":"Kim SG","year":"2014","unstructured":"Kim SG, Kim DM, Woo JT, et al.. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLoS One. 2014, 9:e92843. 10.1371\/journal.pone.0092843","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00948-1","article-title":"Comparative efficacy of lobeglitazone versus pioglitazone on albuminuria in patients with type 2 diabetes mellitus","volume":"12","author":"Kim KS","year":"2021","unstructured":"Kim KS, Hong S, Ahn HY, Park CY. Comparative efficacy of lobeglitazone versus pioglitazone on albuminuria in patients with type 2 diabetes mellitus. Diabetes Ther. 2021, 12:171-81. 10.1007\/s13300-020-00948-1","journal-title":"Diabetes Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12435","article-title":"Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension","volume":"17","author":"Jin SM","year":"2015","unstructured":"Jin SM, Park CY, Cho YM, et al.. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab. 2015, 17:599-602. 10.1111\/dom.12435","journal-title":"Diabetes Obes Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01841-4","article-title":"Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study","volume":"22","author":"Yoo J","year":"2023","unstructured":"Yoo J, Jeon J, Baik M, Kim J. Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. Cardiovasc Diabetol. 2023, 22:106. 10.1186\/s12933-023-01841-4","journal-title":"Cardiovasc Diabetol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200336","article-title":"Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice","volume":"13","author":"Choi BH","year":"2018","unstructured":"Choi BH, Jin Z, Yi CO, et al.. Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice. PLoS One. 2018, 13:e0200336. 10.1371\/journal.pone.0200336","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2013.37.5.349","article-title":"Prevalence of diabetes and prediabetes according to fasting plasma glucose and HbA1c","volume":"37","author":"Jeon JY","year":"2013","unstructured":"Jeon JY, Ko SH, Kwon HS, et al.. Prevalence of diabetes and prediabetes according to fasting plasma glucose and HbA1c. Diabetes Metab J. 2013, 37:349-57. 10.4093\/dmj.2013.37.5.349","journal-title":"Diabetes Metab J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.03.004","article-title":"Synthetic approaches to the 2014 new drugs","volume":"24","author":"Flick AC","year":"2016","unstructured":"Flick AC, Ding HX, Leverett CA, Kyne RE Jr, Liu KK, Fink SJ, O'Donnell CJ. Synthetic approaches to the 2014 new drugs. Bioorg Med Chem. 2016, 24:1937-80. 10.1016\/j.bmc.2016.03.004","journal-title":"Bioorg Med Chem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.023","article-title":"Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-\u03b3 agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects","volume":"33","author":"Kim JW","year":"2011","unstructured":"Kim JW, Kim JR, Yi S, et al.. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-\u03b3 agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Clin Ther. 2011, 33:1819-30. 10.1016\/j.clinthera.2011.09.023","journal-title":"Clin Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S76591","article-title":"Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-\u03b3 agonist, on the pharmacokinetics and pharmacodynamics of warfarin","volume":"9","author":"Jung JA","year":"2015","unstructured":"Jung JA, Lee SY, Kim TE, Kim JR, Kim C, Huh W, Ko JW. Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-\u03b3 agonist, on the pharmacokinetics and pharmacodynamics of warfarin. Drug Des Devel Ther. 2015, 9:737-43. 10.2147\/DDDT.S76591","journal-title":"Drug Des Devel Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.703131","article-title":"Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects","volume":"28","author":"Shin D","year":"2012","unstructured":"Shin D, Kim TE, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. Curr Med Res Opin. 2012, 28:1213-20. 10.1185\/03007995.2012.703131","journal-title":"Curr Med Res Opin"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.06.009","article-title":"Pharmacokinetic interaction between amlodipine and lobeglitazone, a novel peroxisome proliferator-activated receptor-\u03b3 agonist, in healthy subjects","volume":"37","author":"Kim CO","year":"2015","unstructured":"Kim CO, Sil Oh E, Kim C, Park MS. Pharmacokinetic interaction between amlodipine and lobeglitazone, a novel peroxisome proliferator-activated receptor-\u03b3 agonist, in healthy subjects. Clin Ther. 2015, 37:1999-2006.e1. 10.1016\/j.clinthera.2015.06.009","journal-title":"Clin Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18274-1","article-title":"Structural basis for the enhanced anti-diabetic efficacy of lobeglitazone on PPAR\u03b3","volume":"8","author":"Jang JY","year":"2018","unstructured":"Jang JY, Bae H, Lee YJ, et al.. Structural basis for the enhanced anti-diabetic efficacy of lobeglitazone on PPAR\u03b3. Sci Rep. 2018, 8:31. 10.1038\/s41598-017-18274-1","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17082-x","article-title":"Structures of PPAR\u03b3 complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs","volume":"7","author":"Lee MA","year":"2017","unstructured":"Lee MA, Tan L, Yang H, Im YG, Im YJ. Structures of PPAR\u03b3 complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs. Sci Rep. 2017, 7:16837. 10.1038\/s41598-017-17082-x","journal-title":"Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.09.009","article-title":"Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: an open-label extension study","volume":"110","author":"Kim SH","year":"2015","unstructured":"Kim SH, Kim SG, Kim DM, et al.. Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: an open-label extension study. Diabetes Res Clin Pract. 2015, 110:e27-30. 10.1016\/j.diabres.2015.09.009","journal-title":"Diabetes Res Clin Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani N","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012, 142:1592-609. 10.1053\/j.gastro.2012.04.001","journal-title":"Gastroenterology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.1.60","article-title":"Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness","volume":"32","author":"Lee YH","year":"2017","unstructured":"Lee YH, Kim JH, Kim SR, Jin HY, Rhee EJ, Cho YM, Lee BW. Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness. J Korean Med Sci. 2017, 32:60-9. 10.3346\/jkms.2017.32.1.60","journal-title":"J Korean Med Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103927","article-title":"The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity","volume":"100","author":"Rocha RF","year":"2020","unstructured":"Rocha RF, Rodrigues T, Menegatti AC, Bernardes GJ, Terenzi H. The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity. Bioorg Chem. 2020, 100:103927. 10.1016\/j.bioorg.2020.103927","journal-title":"Bioorg Chem"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.04.006","article-title":"The direct effect of lobeglitazone, a new thiazolidinedione, on pancreatic beta cells: a comparison with other thiazolidinediones","volume":"151","author":"Kwon MJ","year":"2019","unstructured":"Kwon MJ, Lee YJ, Jung HS, et al.. The direct effect of lobeglitazone, a new thiazolidinedione, on pancreatic beta cells: a comparison with other thiazolidinediones. Diabetes Res Clin Pract. 2019, 151:209-23. 10.1016\/j.diabres.2019.04.006","journal-title":"Diabetes Res Clin Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05370-2","article-title":"Lobeglitazone attenuates fibrosis in corneal fibroblasts by interrupting TGF-beta-mediated Smad signaling","volume":"260","author":"Nuwormegbe S","year":"2022","unstructured":"Nuwormegbe S, Park NY, Kim SW. Lobeglitazone attenuates fibrosis in corneal fibroblasts by interrupting TGF-beta-mediated Smad signaling. Graefes Arch Clin Exp Ophthalmol. 2022, 260:149-62. 10.1007\/s00417-021-05370-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24378","article-title":"Kinetics of the absorption, distribution, metabolism, and excretion of lobeglitazone, a novel activator of peroxisome proliferator-activated receptor gamma in rats","volume":"104","author":"Lee JH","year":"2015","unstructured":"Lee JH, Noh CK, Yim CS, et al.. Kinetics of the absorption, distribution, metabolism, and excretion of lobeglitazone, a novel activator of peroxisome proliferator-activated receptor gamma in rats. J Pharm Sci. 2015, 104:3049-59. 10.1002\/jps.24378","journal-title":"J Pharm Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101432","article-title":"Lobeglitazone exerts anti-inflammatory effect in lipopolysaccharide-induced bone-marrow derived macrophages","volume":"9","author":"Jeong D","year":"2021","unstructured":"Jeong D, Ko WK, Kim SJ, Han GH, Lee D, Sheen SH, Sohn S. Lobeglitazone exerts anti-inflammatory effect in lipopolysaccharide-induced bone-marrow derived macrophages. Biomedicines. 2021, 9:1432. 10.3390\/biomedicines9101432","journal-title":"Biomedicines"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1045","article-title":"Effects of hepatic impairment on the pharmacokinetic profile and safety of lobeglitazone","volume":"11","author":"Park J","year":"2022","unstructured":"Park J, Kim CO, Oh ES, et al.. Effects of hepatic impairment on the pharmacokinetic profile and safety of lobeglitazone. Clin Pharmacol Drug Dev. 2022, 11:576-84. 10.1002\/cpdd.1045","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0264","article-title":"A real-world study of long-term safety and efficacy of lobeglitazone in Korean patients with type 2 diabetes mellitus","volume":"46","author":"Kim BY","year":"2022","unstructured":"Kim BY, Kwon HS, Kim SK, et al.. A real-world study of long-term safety and efficacy of lobeglitazone in Korean patients with type 2 diabetes mellitus. Diabetes Metab J. 2022, 46:855-65. 10.4093\/dmj.2021.0264","journal-title":"Diabetes Metab J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-014-0197-y","article-title":"Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-\u03b3 agonist, after a single oral administration in healthy female subjects","volume":"34","author":"Park MK","year":"2014","unstructured":"Park MK, Kim TE, Kim J, et al.. Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-\u03b3 agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014, 34:467-74. 10.1007\/s40261-014-0197-y","journal-title":"Clin Drug Investig"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3279-7","article-title":"Diabetes mellitus and risk of hip fractures: a meta-analysis","volume":"27","author":"Fan Y","year":"2016","unstructured":"Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2016, 27:219-28. 10.1007\/s00198-015-3279-7","journal-title":"Osteoporos Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3063","article-title":"A Mendelian randomization study of the effect of type-2 diabetes and glycemic traits on bone mineral density","volume":"32","author":"Ahmad OS","year":"2017","unstructured":"Ahmad OS, Leong A, Miller JA, Morris JA, Forgetta V, Mujammami M, Richards JB. A Mendelian randomization study of the effect of type-2 diabetes and glycemic traits on bone mineral density. J Bone Miner Res. 2017, 32:1072-81. 10.1002\/jbmr.3063","journal-title":"J Bone Miner Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2106","article-title":"In vivo assessment of bone quality in postmenopausal women with type 2 diabetes","volume":"29","author":"Farr JN","year":"2014","unstructured":"Farr JN, Drake MT, Amin S, Melton LJ 3rd, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2014, 29:787-95. 10.1002\/jbmr.2106","journal-title":"J Bone Miner Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2017.41.5.377","article-title":"Effects of lobeglitazone, a novel thiazolidinedione, on bone mineral density in patients with type 2 diabetes mellitus over 52 weeks","volume":"41","author":"Lim S","year":"2017","unstructured":"Lim S, Kim KM, Kim SG, et al.. Effects of lobeglitazone, a novel thiazolidinedione, on bone mineral density in patients with type 2 diabetes mellitus over 52 weeks. Diabetes Metab J. 2017, 41:377-85. 10.4093\/dmj.2017.41.5.377","journal-title":"Diabetes Metab J"},{"key":"ref30","article-title":"Rosiglitazone(BRL-49653)","volume":"59","author":"Yonezawa N","year":"2001","unstructured":"Yonezawa N, Oka Y. Rosiglitazone(BRL-49653). Nihon Rinsho. 2001, 59:2195-9.","journal-title":"Nihon Rinsho"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.113766","article-title":"Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: results of an observational study","volume":"17","author":"Balaji V","year":"2013","unstructured":"Balaji V. Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: results of an observational study. Indian J Endocrinol Metab. 2013, 17:709-15. 10.4103\/2230-8210.113766","journal-title":"Indian J Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.1.7157","article-title":"Rosiglitazone monotherapy is effective in patients with type 2 diabetes","volume":"86","author":"Lebovitz HE","year":"2001","unstructured":"Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001, 86:280-8. 10.1210\/jcem.86.1.7157","journal-title":"J Clin Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2004.05.001","article-title":"Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus","volume":"67","author":"Kim YM","year":"2005","unstructured":"Kim YM, Cha BS, Kim DJ, et al.. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract. 2005, 67:43-52. 10.1016\/j.diabres.2004.05.001","journal-title":"Diabetes Res Clin Pract"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666160421121307","article-title":"Euglycemic diabetic ketoacidosis: a review","volume":"13","author":"Modi A","year":"2017","unstructured":"Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev. 2017, 13:315-21. 10.2174\/1573399812666160421121307","journal-title":"Curr Diabetes Rev"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13546","article-title":"Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: results from the Qatar study","volume":"21","author":"Abdul-Ghani M","year":"2019","unstructured":"Abdul-Ghani M, Migahid O, Megahed A, Singh R, Fawaz M, DeFronzo RA, Jayyousi A. Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: results from the Qatar study. Diabetes Obes Metab. 2019, 21:705-9. 10.1111\/dom.13546","journal-title":"Diabetes Obes Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101030","article-title":"The therapeutic potential of inhibiting PPAR\u03b3 phosphorylation to treat type 2 diabetes","volume":"297","author":"Frkic RL","year":"2021","unstructured":"Frkic RL, Richter K, Bruning JB. The therapeutic potential of inhibiting PPAR\u03b3 phosphorylation to treat type 2 diabetes. J Biol Chem. 2021, 297:101030. 10.1016\/j.jbc.2021.101030","journal-title":"J Biol Chem"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262120-00007","article-title":"Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus","volume":"62","author":"Wagstaff AJ","year":"2002","unstructured":"Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2002, 62:1805-37. 10.2165\/00003495-200262120-00007","journal-title":"Drugs"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2004.6.850","article-title":"Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability","volume":"6","author":"Vasudevan AR","year":"2004","unstructured":"Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther. 2004, 6:850-63. 10.1089\/dia.2004.6.850","journal-title":"Diabetes Technol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/198852-lobeglitazone-and-its-therapeutic-benefits-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:03Z","timestamp":1707509283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/198852-lobeglitazone-and-its-therapeutic-benefits-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.50085","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,6]]}}}